TY - JOUR
T1 - Correlation of tumor location to clinical outcomes in colorectal cancer
T2 - A Single-institution Retrospective Analysis
AU - Signorelli, Carlo
AU - Chilelli, Mario Giovanni
AU - Sperduti, Isabella
AU - Giacinti, Silvana
AU - Amodio, Pietro Maria
AU - Palmieri, Raffaele Macarone
AU - Ranalli, Teresa Valentina
AU - Gomes, Vito Vincenzo
AU - Rosetto, Maria Elena
AU - Nelli, Fabrizio
AU - Ruggeri, Enzo Maria
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background/Aim: Recent data highlighted that location of metastatic colorectal cancer (mCRC) may have a prognostic impact and also a predictive value of the outcomes of first-line therapy. Materials and Methods: The records of mCRC patients who underwent first-line therapy from 2011 to April 2018 at our Institute were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) according to the primary tumor location were investigated. Results: Overall, 130 patients were eligible. Two-year OS was 82.9% in left-sided colon cancers (LCC) and 67.5% in right-sided (RCC) (p=0.32). One-year mPFS was statistically longer in LCC (46.8% vs. 24.2%, p=0.0005). mPFS was longer in LCC treated with anti-VEGF vs. anti-EGFR (p=0.06). ORR was 51.1% in LCC, 25% in RCC (p=0.008). Overall, 11 complete responses all in LCC were observed (p=0.03). Conclusion: Tumor location has a prognostic impact and might influence the outcomes of mCRC patients.
AB - Background/Aim: Recent data highlighted that location of metastatic colorectal cancer (mCRC) may have a prognostic impact and also a predictive value of the outcomes of first-line therapy. Materials and Methods: The records of mCRC patients who underwent first-line therapy from 2011 to April 2018 at our Institute were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) according to the primary tumor location were investigated. Results: Overall, 130 patients were eligible. Two-year OS was 82.9% in left-sided colon cancers (LCC) and 67.5% in right-sided (RCC) (p=0.32). One-year mPFS was statistically longer in LCC (46.8% vs. 24.2%, p=0.0005). mPFS was longer in LCC treated with anti-VEGF vs. anti-EGFR (p=0.06). ORR was 51.1% in LCC, 25% in RCC (p=0.008). Overall, 11 complete responses all in LCC were observed (p=0.03). Conclusion: Tumor location has a prognostic impact and might influence the outcomes of mCRC patients.
KW - First-line therapy
KW - Metastatic colorectal cancer
KW - Tumor location
UR - http://www.scopus.com/inward/record.url?scp=85072168826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072168826&partnerID=8YFLogxK
U2 - 10.21873/anticanres.13679
DO - 10.21873/anticanres.13679
M3 - Article
C2 - 31519596
AN - SCOPUS:85072168826
VL - 39
SP - 4917
EP - 4924
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 9
ER -